Biosimilar developer Samsung Bioepis announced today that it has signed a collaborative agreement with Takeda to co-develop multiple novel biologic drugs that will target currently unmet needs.
Biosimilar developer Samsung Bioepis announced today that it has signed a collaborative agreement with Takeda to co-develop multiple novel biologic drugs that will target currently unmet needs. The companies’ first project, which they will begin developing immediately, is TAK-671, a prospective treatment for severe acute pancreatitis.
The agreement marks the first foray into novel biologics for Incheon-based Samsung Bioepis; the company has thus far focused entirely on developing biosimilar treatments. Christopher Hansung Ko, president and CEO of Samsung Bioepis, called the agreement a new chapter in the company’s history, and said that “[5] years ago, we entered the biopharmaceutical industry with a strong determination to transform the way therapies are brought to patients by replacing legacy processes with new and innovative ones. Together with Takeda, we look forward to realizing this goal vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”
Takeda’s head of the center for external innovation, Daniel Curran, MD, said that it looked forward to the companies’ collaboration and its ability to fuse “our unique capabilities in development and manufacturing along with fresh and innovative clinical approaches.”
BioPharma Dive suggests that Samsung Bioepis’ move to diversify its pipeline could provide the company with a cushion as it waits to reap the rewards of its investments in the biosimilar space. Samsung Bioepis has invested approximately $1.3 billion in biosimilar research and development since it was founded in 2012.
So far, the company has earned $250 million in sales for its etanercept biosimilar, marketed as Benepali, since it launched in the European Union (EU). The company has also gained EU and US approval for its biosimilar infliximab (Renflexis), which launched in the US market in July 2017. It is also awaiting European Medicines Agency decisions on its adalimumab and trastuzumab biosimilars. In the United States, the company is looking ahead to final FDA approval of its follow-on insulin glargine, developed in partnership with Merck, following conclusion of a litigation over a patent dispute with Lantus’ sponsor, Sanofi.
Despite a delay in seeing returns on its substantial investments, Samsung Bioepis does not show signs of backing away from its biosimilar development; the company is currently in phase 3 clinical trials with its SB8, a proposed bevacizumab biosimilar.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
August 22nd 2024Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.